|By PR Newswire||
|September 3, 2014 06:00 AM EDT||
SAN DIEGO, Sept. 3, 2014 /PRNewswire/ -- Ajinomoto Althea, Inc. ("Althea"), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate issued by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA conducted an on-site inspection on June 19, 2014 that yielded no critical or major observations. This certification provides clearance to Althea to test commercial drug product for the European market. By issuing this certification, the MHRA officially recognizes that Althea's quality control testing and overall quality systems are in strict compliance with the European GMP requirements.
"Althea is proud of this important regulatory milestone. We are well known for our impeccable regulatory track record in the US and now are very pleased to expand our commercial testing capabilities for European clients," stated David Enloe, President and CEO of Althea. "Knowing that our testing and quality processes meet both the stringent FDA and EMA quality requirements really signifies a great accomplishment by our team and supports our leadership position in the CMO market."
In addition to pursuing European GMP approval, Althea continues to invest and expand in quality systems, facilities and operational capabilities to support the increased demand that the company has experienced in both its biologics manufacturing (drug substance) and fill and finish (drug product) business segments. Althea provides a broad range of manufacturing service capabilities including cGMP bulk manufacturing filling in vials and syringes, microbial-based biologics manufacturing, Crystalomics® crystal suspension technology, process development, in-process and release testing analytics, equipment qualification, and validation.
About Ajinomoto Althea, Inc.
Ajinomoto Althea, Inc. is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services. Ajinomoto Althea, Inc. offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Ajinomoto Althea, Inc. offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Ajinomoto Althea Inc.'s formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. Ajinomoto Althea also has an innovative and proven recombinant protein expression technology called Corynex® technology. For more information visit us at www.altheatech.com.
SOURCE Ajinomoto Althea, Inc.
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Sep. 29, 2016 04:30 PM EDT Reads: 1,331
Whether they’re located in a public, private, or hybrid cloud environment, cloud technologies are constantly evolving. While the innovation is exciting, the end mission of delivering business value and rapidly producing incremental product features is paramount. In his session at @DevOpsSummit at 19th Cloud Expo, Kiran Chitturi, CTO Architect at Sungard AS, will discuss DevOps culture, its evolution of frameworks and technologies, and how it is achieving maturity. He will also cover various st...
Sep. 29, 2016 04:30 PM EDT Reads: 1,934
Sep. 29, 2016 04:00 PM EDT Reads: 443
Sep. 29, 2016 04:00 PM EDT Reads: 2,360
Sep. 29, 2016 03:45 PM EDT Reads: 2,179
Sep. 29, 2016 03:30 PM EDT Reads: 1,613
Sep. 29, 2016 03:30 PM EDT Reads: 2,518
Sep. 29, 2016 03:15 PM EDT Reads: 1,770
Sep. 29, 2016 03:00 PM EDT Reads: 2,961
Sep. 29, 2016 03:00 PM EDT Reads: 2,761
Sep. 29, 2016 02:00 PM EDT Reads: 4,178
Sep. 29, 2016 02:00 PM EDT Reads: 1,155
Sep. 29, 2016 02:00 PM EDT Reads: 3,937
Sep. 29, 2016 02:00 PM EDT Reads: 3,604
Most of us already know that adopting new cloud applications can boost a business’s productivity by enabling organizations to be more agile and ready to change course in our fast-moving and connected digital world. But the rapid adoption of cloud apps and services also brings with it profound security threats, including visibility and control challenges that aren’t present in traditional on-premises environments. At the same time, the cloud – because of its interconnected, flexible and adaptable...
Sep. 29, 2016 01:45 PM EDT Reads: 1,785